FDA Approval of LYNPARZA® in US for HRR gene-mutated mCRPC

Dr. Josefa Briceno, M.D., Medical Head for the DNA Damage Response Franchise in US Medical Affairs at AstraZeneca discusses the recent FDA approval of LYNPARZA® (olaparib) for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone.  Approval was based on results from the Phase III PROfound trial, which were published in the “New England Journal of Medicine”.

Dr. Briceno is a Surgical Oncologist by training who practiced for 13 years prior to working for AstraZeneca. At AZ she serves as the Medical Head for the DNA Damage Response (DDR) Franchise in US Medical Affairs, overseeing Lynparza across several indications, including Prostate Cancer.

Liked it? Take a second to support healthprofessionalradio on Patreon!

0 Comments

Leave a Reply

You must be logged in to post a comment.